Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

27,705 signal articles · 237 in last 24h · 134,276 total before filter · latest 21m ago
237last 24h
1111last 7d
179● bullish (7d)
133● bearish (7d)
209publishers
AllMacro294Earnings370M&A76Regulatory27Product11Analyst15
Sentiment:bullishneutralbearishshow all (incl. clickbait)
Investing.com6d agobearish
Iranian trade plunges 35% as U.S. steps up economic pressure

Investing.com -- Iran’s foreign trade has fallen nearly 35% under U.S. sanctions and a naval blockade, President Masoud Pezeshkian said, as Tehran’s leadership acknowledged mounting economic pressure six months into the war, Reuters reported exclusively.

Solstice (SOLS) Jumps 12.8% on Merger Exit, $500M Buyback
Insider Monkey6d agobullish
Solstice (SOLS) Jumps 12.8% on Merger Exit, $500M Buyback

Solstice Advanced Materials (NASDAQ:SOLS) jumped by 12.76 percent on Friday to finish at $63.53 apiece after abandoning a plan to acquire Element Solutions for $14.5 billion, while investors also cheered a $500 million share buyback program. In a statement, the company said that it entered into an agreement with Element Solutions to formally terminate their […]

Pharma Industry Stares Down Biggest Patent Cliff in Decades
The Wall Street Journal6d agoneutral
Pharma Industry Stares Down Biggest Patent Cliff in Decades

For drugmakers, a clock starts before a drug is even approved: Patents run out, lower-priced copycats flood in and sales collapse. The pharma industry is entering its biggest wave of patent expirations in decades. The world’s bestselling drug in 2025, Merck’s cancer immunotherapy Keytruda, loses U.S. patent protection in 2028, and nearly every pharma company has at least one blockbuster drug that will go off patent in the next five years.

Marvell Technology (MRVL) Shares Fell After Earnings
Simply Wall St.6d agoneutral
Marvell Technology (MRVL) Shares Fell After Earnings

Marvell Technology (NasdaqGS:MRVL) reported strong quarterly results and raised near term and long term revenue guidance, yet the stock fell after the earnings release. The company lifted its fiscal 2027 and 2028 revenue outlook, pointing to building momentum in data center demand and AI related growth drivers. The post earnings share price reaction highlighted that investor expectations for AI exposure remain very high, even when companies report solid operational performance. For a...

SentinelOne Q2 Earnings Call Highlights
MarketBeat6d agoneutral
SentinelOne Q2 Earnings Call Highlights

SentinelOne (NYSE:S) reported second-quarter fiscal 2027 results that exceeded its guidance for revenue, operating income and earnings per share, as the cybersecurity company cited growth in artificial intelligence security, cloud and data offerings alongside continued endpoint demand. Revenue for